๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Cambridge
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Cambridge

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 675 Birmingham 472 Glasgow 439 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
416 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
2,380
Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford
2026-12-16
Not yet open
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
NCT07032038Sensorineural Hearing Loss, Presbyacusis, Auditory Neuropathy
Rinri Therapeutics
Phase 1/2
20
Birmingham, Cambridge, London
2026-11
Not yet open
Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes
NCT07401901Type 1 Diabetes (T1D)
Medtronic MiniMed, Inc.
Not applicable
230
Cambridge, Leicester, Manchester
2026-10-15
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200Essential Thrombocythemia
Incyte Corporation
Phase 3
426
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
2026-09-08
Recruiting
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd
Phase 1
50
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton
2026-09
Recruiting
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
472
Cambridge
2026-08-20
Recruiting
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants
NCT07789899Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 1
24
Cambridge
2026-08-18
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Swedish Orphan Biovitrum
Phase 4
150
Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford
2026-08-05
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Bristol, Cambridge, Preston, Sheffield
2026-07-16
Recruiting
DAREONยฎ-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
Boehringer Ingelheim
Phase 3
390
Cambridge, Edinburgh, Manchester
2026-07-10
Recruiting
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
NCT07124078Chronic Graft-versus-host-disease
Incyte Corporation
Phase 2
60
Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield
2026-05-20
Recruiting
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
NCT07427394Advanced Breast Cancer
AstraZeneca
Phase 2
24
Cambridge, London, Manchester
2026-05-06
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
590
Cambridge, London
2026-04-23
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332Pulmonary Arterial Hypertension
Inhibikase Therapeutics
Phase 3
486
Cambridge, Glasgow, London
2026-04-23
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3
736
Cambridge, London, Sutton
2026-04-22
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
Boehringer Ingelheim
Phase 2
405
Basingstoke, Belfast, Cambridge, Doncaster, London
2026-04-20
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
CatalYm GmbH
Phase 2/3
518
Brighton, Cambridge, Dundee, Guildford, Manchester, Newcastle upon Tyne
2026-04-16
Recruiting
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
NCT07158242Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
100
Birmingham, Cambridge, Sheffield
2026-04-15
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
Birmingham, Salford, London, Cambridge
2026-04-07
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Cambridge, Cardiff, London, Southampton
2026-04-02
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb
Phase 1/2
474
London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey
2026-03-26
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-03-24
Rows per page Showing 1–25 of 416
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-uk/city/cambridge

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.